Cargando…

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland

PURPOSE: Sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin has recently been shown to improve the outcomes of heart failure (HF) patients regardless of patient’s left ventricular ejection fraction by reducing the combined risk of cardiovascular death or hospitalization for worsening HF....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hallinen, Taru, Kivelä, Santtu, Soini, Erkki, Harjola, Veli-Pekka, Pesonen, Mari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831000/ https://www.ncbi.nlm.nih.gov/pubmed/36636485 http://dx.doi.org/10.2147/CEOR.S391455

Ejemplares similares

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
por: Soini, Erkki J., et al.
Publicado: (2015)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data
por: Hallinen, Taru, et al.
Publicado: (2014)

Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management
por: Soini, Erkki, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
por: Ong, Siew Chin, et al.
Publicado: (2023)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders
por: Hallinen, Taru, et al.
Publicado: (2012)

Primary-care-based episodes of care and their costs in a three-month follow-up in Finland
por: Heinonen, J., et al.
Publicado: (2015)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Cost‐effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov‐model
por: Pesonen, Mari, et al.
Publicado: (2021)

Standardized spider (Arachnida, Araneae) inventory of Hankoniemi, Finland
por: Cardoso, Pedro, et al.
Publicado: (2017)

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2022)

Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998–2015
por: Holmberg, Ville, et al.
Publicado: (2019)

Multidrug-resistant tuberculosis in Finland: treatment outcome and the role of whole-genome sequencing
por: Korhonen, Virve, et al.
Publicado: (2022)

Cost-effectiveness analysis of guidelines for antihypertensive care in Finland
por: Booth, Neill, et al.
Publicado: (2007)

Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure
por: Öhman, Jonas, et al.
Publicado: (2017)

Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2023)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Type 1 tyrosinemia in Finland: a nationwide study
por: Äärelä, Linnea, et al.
Publicado: (2020)

Characteristics and costs of electric scooter injuries in Helsinki: a retrospective cohort study
por: Vasara, Henri, et al.
Publicado: (2022)

Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model
por: Reynolds, Matthew R, et al.
Publicado: (2013)

Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland
por: Puolitaival, Antti, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

Comparison of the use of comprehensive point-of-care test panel to conventional laboratory process in emergency department
por: Kankaanpää, Meri, et al.
Publicado: (2018)

Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

It is cost effective to improve the standard of care for women experiencing miscarriage
por: Sonalkar, Sarita, et al.
Publicado: (2019)

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
por: Soini, Erkki, et al.
Publicado: (2017)

Trends in the use and costs of round-the-clock long-term care in the last two years of life among old people between 2002 and 2013 in Finland
por: Forma, Leena, et al.
Publicado: (2017)

Tuberculosis screening of asylum seekers in Finland, 2015–2016
por: Räisänen, Pirre E., et al.
Publicado: (2020)

Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Use of point-of-care testing and early assessment model reduces length of stay for ambulatory patients in an emergency department
por: Kankaanpää, Meri, et al.
Publicado: (2016)

Costes standard /
por: Bennett, Clinton W.
Publicado: (1967)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Standards of Care in Pediatrics
por: Heider, Diane
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jmohbn0239cb4qonu7820dqe2g